In a UK-based observational trial data published in the journal Neuropediatrics, daily administration of cannabis products is associated with lowering seizure frequency among children with TRE.
Safety and efficacy of cannabis-derived products were assessed in 35 patients diagnosed with pediatric epilepsy. The study subjects were partakers of the UK Medical Cannabis Registry and they possessed a doctor’s authorization to consume cannabis. During the study trials, subjects were asked to take either CBD-dominant extract oils or a combination therapy consisting of both CBD and THC.
Results were favorably inclined toward the effectiveness of cannabis-based medicinal products in children with TRE, especially in the group of patients treated with delta-9-THC. At 6 months, 90 percent of the subjects treated with the combination therapy exhibited over 50 percent reduction in seizure frequency while less than one-third of patients who consumed CBD-only products did so. The authors added that temporary adverse effects were well tolerated.
The conclusions from this study could be used in designing future phase II randomized controlled trials, chiefly on dosing regimens. In Canada, survey data estimates that as many as a third of epileptic patients consuming CBD products for therapeutic purposes showed symptomatic improvements after cannabis therapy.
Regulators have been granting CBMPs (Cannabis-based medicinal products) market approval.
Five years ago, the US Food and Drug Administration approved Epidiolex, a plant-derived CBD prescription drug, for the treatment of two rare forms of pediatric epilepsy - Lennox-Gastaut syndrome, and Dravet syndrome. In 2020, the prescription use of Epidiolex expanded to include patients with the genetic disorder tuberous sclerosis complex (TSC).
Cannabis medicinal products continue to show strong clinical outcomes. This is heyday news for pharmaceutical THC/CBD suppliers and companies.